JAPAN · PHARMACEUTICALS · EXPANSION BRIEF

Japan prescription drugs 2026: AI impact and use cases

Where does automation pay back first, and where does it stall?

Executive summary

The tension: price cuts every April shrink budgets just as staff shortages make automation unavoidable. Sell time back to clinical, pharmacy and sales teams first; treat discovery and patient-facing software as options, not the entry.

Labour, not cost, drives the case. Medical representatives fell 6.6% in a year to 43,646, and pharmacists record guidance for 896 mn prescriptions a year.

Document work already shows results. A cancer centre cut report drafting from 120 to 78 working days; Shionogi cut trial programming hours by 30%.

Report details

Published
2026-10-30
Pages
41
Format
PDF
Code
JP-PHA-XPN-D26-01
Market
Japan
Industry
Pharmaceuticals
Year
2026

Table of contents · 8 sections

  1. 04 Executive summary
  2. 05 Exposure and starting points
  3. 06 Processes, products and journeys that change
  4. 07 Value and feasibility
  5. 08 Rules, risks and suppliers
  6. 09 Where a foreign company fits and the order to move
  7. 10 Who's who
  8. 11 Methodology and sources

The full report is available to subscribers and buyers. The executive summary above is free to read.

Key questions

What share of hospitals in Japan issue e-prescriptions?

Only 19.4% of hospitals with online eligibility checks issued e-prescriptions in March 2026, up from 13.4% in June 2025, according to KIRA's 2026 AI impact and use cases [Digital Agency 2026].

Source: Digital Agency 2026, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How many pharmacies in Japan could use AI record drafting?

Japan had 63,203 pharmacies at end-FY2024, and Ain plans to roll out record drafting to about 1,300 by April 2027, according to KIRA's 2026 AI impact and use cases [CREX 2026]; [Ain 2026].

Source: CREX 2026, 2024 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How should a foreign company enter AI-led work in Japanese prescription drugs?

KIRA ranks a drafting and programming module sold inside an integrator or CRO first by speed to revenue, with the first proof a time saved on one past report against a control, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How much value could AI create in Japan's prescription drug industry by 2030?

KIRA estimates the largest value pools in Japan's prescription drug industry at JPY 50-120 bn a year for MR and medical work and JPY 40-100 bn for pharmacy records by 2030, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2030 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How mature are Japan's local pharma players in AI?

In KIRA's October 2026 outside-in maturity scores, Astellas scores 5 of 5 on models in production, while mid-size generic makers score 1, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Which Japanese integrators work with AI drug developers?

Fujitsu works with Medipal and THERS, and SoftBank works with Chugai, and both own the buyer relationship and the contract, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Which AI use cases in Japanese prescription drugs are ready to act on now?

Four use cases are ready now in Japanese prescription drugs: clinical study report and protocol drafting, trial statistical programming, pharmacy medication-history drafting and MR visit preparation, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

Which AI use cases in Japan need a pilot before they scale?

Four use cases need a pilot first in Japan: demand forecasting and warehouse picking, trial patient finding, safety case intake and patient finding for disease awareness, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How much did clinical study report drafting time fall in Japan?

Clinical study report drafting fell from 120 to 78 working days at the National Cancer Center Hospital, according to KIRA's 2026 AI impact and use cases [MHLW grant 2025].

Source: MHLW grant 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How much time has automation saved in drug development cases in Japan?

Owner-disclosed savings from live cases in Japan include about 70% less time from hit to drug candidate, for successful cases only [Astellas 2024], and 35% less time on clinical study report drafting, according to KIRA's 2026 AI impact and use cases.

Source: Astellas 2024, 2024 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

How many AI medical software programs are approved in Japan?

45 AI medical programs were approved in Japan out of 296 medical software approvals to March 2025, none of them generative, according to KIRA's 2026 AI impact and use cases [MHLW SaMD 2025].

Source: MHLW SaMD 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

When did Japan pass the AI Promotion Act?

Japan's AI Promotion Act passed on 28 May 2025; it promotes AI and has no penalties, so sector rules govern, according to KIRA's 2026 AI impact and use cases [AI Act JP 2025].

Source: AI Act JP 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

What did Japan's amended pharmaceutical law change for pharmacies?

The amended PMD Act, in force from May 2025, allows pharmacies to outsource some dispensing work, which favours large chains and central fill, according to KIRA's 2026 AI impact and use cases [PMD Act 2025].

Source: PMD Act 2025, 2025 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

What did Chugai drop from its antibody design work?

Chugai dropped BRY10, its only clinical antibody designed with its own AI tooling, in 2026, which shows discovery and patient data still stall, according to KIRA's 2026 AI impact and use cases [Fierce 2026].

Source: Fierce 2026, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

What is the top risk of AI in Japanese drug documents?

Wrong content in a regulated document is rated likelihood 3 and impact 5 of 5, the highest-impact risk on KIRA's list, mitigated by reviewer sign-off and logged edits, according to KIRA's 2026 AI impact and use cases.

Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: AI impact and use cases

More on Prescription drugs in Japan